Clinical Trials Logo

Critical Limb Ischemia (CLI) clinical trials

View clinical trials related to Critical Limb Ischemia (CLI).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05208905 Active, not recruiting - Clinical trials for Critical Limb Ischemia (CLI)

LIFE-BTK PK Sub-study

Start date: February 10, 2022
Phase: N/A
Study type: Interventional

LIFE-BTK PK is a prospective, single-arm, open-label, non-blinded, non-randomized sub-study of LIFE-BTK Randomized Controlled Trial (NCT04227899), that will enroll approximately 7 subjects in the United States (US) and outside the US with a maximum of 5 sites in the US. Of the 7 subjects planned to be enrolled, 4 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom drug-coated balloons (DCB) were not used; 3 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom DCB were used for treatment of inflow disease.

NCT ID: NCT04227899 Active, not recruiting - Clinical trials for Critical Limb Ischemia (CLI)

LIFE-BTK Randomized Controlled Trial

LIFE-BTK
Start date: August 18, 2020
Phase: N/A
Study type: Interventional

The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be randomized in a 2:1 ratio. The clinical investigation will be conducted at approximately 65 clinical sites in the US, Asia, Australia, and New Zealand.

NCT ID: NCT03006770 Active, not recruiting - Clinical trials for Critical Limb Ischemia (CLI)

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Start date: May 22, 2017
Phase: Phase 3
Study type: Interventional

This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Tissue Loss (Rutherford Category 5) who are Unsuitable for Revascularization.